新型芳香吲唑酮类化合物的合成与表征

以p-取代苯胺为原料,经重氮化反应后再与2-氯乙酰乙酸乙酯反应制得(Z)-4-[2-(1-氯-2-乙氧基-2-羰亚甲基)肼基]-取代苯(2a～2i);在无水乙醇中,2a～2i分别与5,5-二甲基-1,3-环己二酮发生环化反应合成了9个新型的芳香吲唑类化合物(3a～3i),其结构经1H NMR和MS表征.     

含酚醚中心功能基的大二环型穴醚的合成及配位性能

4-氯-2, 6-二羟基苯甲醚(2)与氯乙酸钠缩合, 制得4-氯-2, 6-二(羟甲氧基甲基)苯甲醚(4), 由4经酰氯化生成4-氯-2, 6-二(3-氯甲酰基-2-氧杂丙基)苯甲醚(5)后, 再与相应的二氮杂冠醚3a, 3b和3c反应制备标题化合物1a~1c。用1^H NMR法研究了1a~1c对碱金属离子的配位性能, 讨论了分子内的中心功能基和底环大小对其IR, 1^H NMR和配位行为的影响。     

α-二酮的铟促水相烯丙基化研究

以6,7-十二烷二酮(或1,2-环烷基二酮)和3-碘-2-碘甲基-1-丙烯为原料,铟粉为催化剂,在水相中经烯丙基化反应合成了4个新型的单烯丙基化产物[7-羟基-7-(2-碘甲基-烯丙基)-十二烷-6-酮和2-羟基-2-(2-碘甲基-烯丙基)-环烷酮]和3个新型的双烯丙基化产物{4-亚甲基-1,2-二戊基-1,2-环戊二醇,2-羟基-2-[2-(1-羟基-2-羰基-环癸基甲基)-烯丙基]-环癸酮和2-羟基-2-[2-(1-羟基-2-羰基-环十二基甲基)-烯丙基]-环十二烷酮},其结构经1H NMR,IR和HR-MS表征。     

3-(2-氯-4-三氟甲基苯氧基)苯甲酸酯的合成、晶体结构及生物活性

以3-(2-氯-4-三氟甲基苯氧基)苯甲酸为起始原料,经氯化亚砜氯化后得中间体3-(2-氯-4-三氟甲基苯氧基)苯甲酰氯(1),再与不同取代的苯酚反应,合成了13个未见文献报道的3-(2-氯-4-三氟甲基苯氧基)苯甲酸酯(2).通过1H NMR,IR,EI-MS和元素分析对所合成的化合物进行了结构表征,3-甲基苯基3-(2-氯-4-三氟甲基苯氧)苯甲酸酯(2f)通过单晶X射线衍射进一步确证结构.初步的除草活性测试结果表明:大多数目标化合物在1.5 kg/ha剂量下对双子叶植物油菜和苋菜具有较高的抑制活性.     

乐伐替尼的合成

以4-氨基-2-甲氧基苯甲酸甲酯为原料,与米氏酸、原甲酸三甲酯发生缩合得到4-[(2,2-二甲基-4,6-二氧代-1,3-二噁烷-5-亚甲基)氨基]-2-甲氧基苯甲酸甲酯(4),随后经环合、氯代、氨化反应生成4-氯-7-甲氧基喹啉-6-甲酰胺(7)。7与3-氯-4-氨基苯酚盐酸盐反应制得4-(4-氨基-3-氯苯氧基)-7-甲氧基喹啉-6-甲酰胺(8),最后与氯甲酸苯酯、环丙胺经一锅反应制得乐伐替尼。目标产物结构经核磁、质谱分析得到确证,总收率约34%(以4-氨基-2-甲氧基苯甲酸甲酯计)。改进后的工艺操作简单,降低了原料成本,且各步反应收率较高。     

9-(β-D-2''-脱氧核糖基)-6-甲基嘌呤的合成

报道了9-(β-D-2'-脱氧核糖基)-6-甲基嘌呤合成的新方法.以肌苷1为原料,经酯化、氯化、氨解得6-氯嘌呤核苷(4),再经过羟基保护、6-位甲基化反应及脱保护反应得到关键中间体6-甲基嘌呤核苷7,用1,3-二氯-1,1,3,3-四异丙基二硅氧烷保护7核糖上的3,5-二羟基,2-羟基与苯氧基硫代甲酰氯反应后得到9,然后与氢化三正丁基锡[HSn(Bu-n)3]还原脱氧,最后脱保护得到目标化合物11.产物结构经MS,1HNMR,元素分析等鉴定.     

新型6-氯-4(3H)-喹唑啉酮类Schiff碱的合成及其抑菌活性

以6-氯邻氨基苯甲酸为起始原料,与醋酐酰化关环制得6-氯-2-甲基噁嗪-4-酮(1);1在80%水合肼中回流反应制得6-氯-2-甲基-3-氨基-4(3H)-喹唑啉酮(2);2与羟基芳醛反应合成了4种新型的6-氯-4(3H)-喹唑啉酮类Schiff碱(4a~4d),其结构经1H NMR,13C NMR,IR和元素分析表征。采用琼脂扩散法研究了4a~4d对金黄色葡萄球菌(A)、大肠杆菌(B)和枯草杆菌(C)的抑制活性。结果表明:用药浓度为300 mg·m L~(-1)时,4a~4d对A~C均有一定的抑制活性,其中6-氯-2-甲基-3-(5-甲基-2-羟基苯亚甲氨基)-4(3H)-喹唑啉酮(4c)抑菌活性最强,对A~C的抑菌圈直径分别为8.8 mm,11.9 mm和9.6 mm。     

新型螺[色烯并(2,3-c)吡唑-4,1’-异苯并呋喃]-3’-酮类化合物的合成及光学性能研究

在酸催化及脱水作用下,以2-(4-二丁基氨基-2-羟基苯甲酰基)苯甲酸或2-(4-二乙基氨基-2-羟基苯甲酰基)苯甲酸和吡唑啉酮为原料,通过Knoevenagel缩合和脱水反应,合成了一系列新型螺[色烯并(2,3-c)吡唑-4,1’-异苯并呋喃]-3’-酮类化合物.考察了反应物配比、催化剂、温度和时间等因素对反应的影响,初步探究了所合成化合物在不同pH、溶剂中的光学性能,其中1-(4-氯苯基)-7-(二乙基氨基)-3-甲基-1H,3’H-螺[色烯并[2,3-c]吡唑-4,1’-异苯并呋喃]-3’-酮(1e)和1-(4-氯苯基)-7-(二丁基氨基)-3-甲基-1H,3’H-螺[色烯并[2,3-c]吡唑-4,1’-异苯并呋喃]-3’-酮(1j)有潜力作为强酸强碱的pH指示剂.     

新型吡咯并三嗪酮类PARP-1抑制剂的设计、合成及生物活性

分别以5-溴-2-氟苯甲腈(1a)和3-溴苯甲腈(1b)为原料,经Sonogashira偶联,脱三甲基硅基保护基,三分子偶联及水解等5步反应制得中间体2-氟-5-［(4-氧代-3,4-二氢吡咯［1,2-d］［1,2,4］三嗪-1-基)甲基］苯甲酸（6a)和3-[(4-氧代-3,4-二氢吡咯［1,2-d］［1,2,4］三嗪-1-基)甲基］苯甲酸（6b）。环烷基甲酸经酰氯化,缩合和脱Boc保护基3步反应制得环烷基哌嗪-1-基甲酮(7a~7c)。 6a与NCS（1 eq.）反应制得5-［(6-氯-4氧代-3,4二氢吡咯［1,2-d］［1,2,4］三嗪-1-基)甲基］-2氟 苯甲酸(6c); 6a与NCS(2 eq.)反应制得5-［(6,7-二氯-4氧代-3,4二氢吡咯［1,2-d］［1,2,4］三嗪-1-基)甲基］-2氟-苯甲酸(6d)。 6a~6d, 6a~6c分别与7a~7c和1-（2-嘧啶基）哌嗪在TBTU（缩合剂）,DIPEA（碱）的作用下合成了13个新型吡咯并三嗪酮类PARP-1抑制剂(8a~8m),其结构经¹HNMR和MS(ESI)表征。采用Alarm blue法研究了8a~8m对肿瘤细胞MDA-MB-436的抑制活性(IC₅₀)。结果表明：8f, 8g, 8i和8j对MDA-MB-436有较强的抑制活性（IC₅₀=30.5~69.3 nmol·L^-1）。     

尼达尼布的合成

间硝基苯甲酸甲酯(1)与氯乙酸甲酯反应制得4-甲氧基羰基甲基-3-硝基苯甲酸甲酯(2);2依次经催化氢化、乙酰化及与原苯甲酸三乙酯反应制得关键中间体(E)-1-乙酰基-3-(乙氧基-苯基-甲烯基)-2-氧-2,3-二氢-1H-吲哚-6-羧甲酸甲酯(5);N-甲基对硝基苯胺依次经氯乙酰化、取代和催化氢化反应制得N-(4-氨基苯基)-N-甲基-2-(4-甲基哌嗪-1-基)乙酰胺(9);5和9经拼合合成了治疗特发性肺纤维化药尼达尼布,总收率22.0%,纯度99.4%,其结构经1H NMR和MS确证。     

Synthesis of 3-amino-3,4-dihydroquinazolin-4-one derivatives from anthranilic acid hydrazide and dicarboxylic acids

Treatment of anthranilic acid hydrazide with 2 equiv of ethoxalyl chloride gave the corresponding diester which underwent cyclization in acetic anhydride to produce ethyl 3-(ethoxalylamino)-4-oxo-3,4-dihydroquinazoline-2-carboxylate. Acylation of anthranilic acid hydrazide first with succinic anhydride and then with ethoxalyl chloride led to the formation of 4-[2-(2-{[ethoxy(oxo)acetyl]amino}benzoyl)hydrazino]-4-oxobutanoic acid whose cyclization in acetic acid afforded N-(2-ethoxycarbonyl-4-oxo-3,4-dihydroquinazolin-3-yl)succinamic acid, while in acetic anhydride ethyl 3-(2,5-dioxopyrrolidin-1-yl)-4-oxo-3,4-dihydroquinazoline-2-carboxylate was obtained. The latter was brought into reactions with amines and hydrazine hydrate and alkaline hydrolysis. Acylation of 2-[2-(2-aminobenzoyl)hydrazinocarbonyl]benzoic acid with ethoxalyl chloride gave ethyl N-[2-(phthalimidocarbamoyl)phenyl]oxamate, and with succinic anhydride, 3-[4-oxo-3-phthalimido-3,4-dihydroquinazolin-2-yl]propionic acid. 4-[2-(2-Aminobenzoyl)hydrazino]-4-oxobutanoic acid reacted with phthalic anhydride in boiling acetic acid to give phthalazino[1,2-b]quinazoline-5,8-dione via elimination of succinic acid residue.     

Synthesis of phenylacetylene containing 1,2,3-triazole group

Bromination of (E)-1-[4-(2-carboxy-vinyl)phenyl]-[1,2,3]triazole-4-carboxylic acid ethyl ester, which was synthesized in 90% yield by a Huisgen-type [3 + 2]-cycloaddition reaction between 3-(4-azidophenyl) acrylic acid and ethyl propiolate, in CHCl₃ followed by a debrominative decarboxylation reaction with Et₃N in DMF under microwave irradiation condition afforded stereoselective (Z)-1-(4-(2-bromovinyl)phenyl)-1,2,3-triazole-4-carboxylic acid ethyl ester in 94% yield. Treatment of (Z)-1-(4-(2-bromovinyl)phenyl)-1,2,3-triazole-4-carboxylic acid ethyl ester with EtONa in DMF afforded 1-(4-ethynylphenyl)-1,2,3-triazole-4-carboxylic acid ethyl ester in a yield of 90%.     

达比加群酯中间体3-【【【2-{[(4-氰基苯基)氨基]甲基}-1-甲基-1H-苯并咪唑-5-基】羰基】(吡啶-2-基)氨基】丙酸乙酯的合成

以对氨基苯腈为起始原料,经胺化反应制得N-(4-氰基苯基)甘氨酸(4);4与N-[3-氨基-4-(甲基氨基)苯甲酰基]-N-2-吡啶-β-丙氨酸乙酯(5)经酰胺化后经闭环反应,合成了达比加群酯的关键中间体——3-【【【2-{[(4-氰基苯基)氨基]甲基}-1-甲基-1H-苯并咪唑-5-基】羰基】(吡啶-2-基)氨基】丙酸乙酯,总收率79.6%,其结构经~1H NMR和ESI-MS确证。     

达比加群酯的合成

3-硝基-4-氯苯甲酸(2)经甲胺化得3-硝基-4-甲氨基苯甲酸(3),2-氨基吡啶与丙烯酸乙酯经迈克尔加成得3-[(吡啶-2-基)氨基]丙酸乙酯(5),化合物3与5经缩合、催化氢化得3-{[(3-氨基-4-甲胺基)苯甲酰基](吡啶-2-基)氨基}丙酸乙酯(7),化合物7再与N-(4-氰基苯基)甘氨酸(8)酰化、环合和Pinner反应,最后与氯甲酸正己酯反应得到达比加群酯(1),总收率约40%(以3-硝基-4-氯苯甲酸计),结构经IR、1H NMR和MS测试技术确证。     

Stereospecific substitution of enantiomerically pure 1-(2-pyridinyl)ethyl methanesulfonate with beta-dicarbony compounds

The alkylation of the sodium salt of the malonic acid diester with (R)-1-(2-pyridinyl)ethyl methanesulfonate (2) gave the dimethyl (R)-[1-(2-pyridinyl)ethyl]malonate (3a), stereospecifically. The alkylation reaction of methyl acetoacetate gave the methyl (2'S,2R/2S)-3-oxo-2-[1-(2-pyridinyl)ethyl]butanoate (3d) along with the methyl (S)-3-[1-(2-pyridinyl)ethoxy]-2-butenoate (4d). The acid hydrolysis and decarboxylation of 3d under acidic conditions gave (R)-4-(2-pyridinyl)pentan-2-one (6), and the alkylation of methyl (R)-[1-(2-pyridinyl)ethyl]acetoacetate with benzyl bromide gave a mixture of C-benzylated and O-benzylated products 7 and 8.     

Imidazo[2,1-b]benzothiazoles. II. Synthesis and antiinflammatory activity of some imidazo[2,1-b]benzothiazoles

3-[2-[p-(Un)substituted phenyl]imidazo [2,1-b]benzothiazol-3- yl]propionic acid derivatives (2a--e) were prepared via the interaction of the corresponding 2-[p-(un)substituted phenyl]imidazo[2,1-b]benzothiazoles (1a--e) with acrylic acid in the presence of acetic anhydride and acetic acid. Esterification of 2a--e produced methyl esters (3a--e). Upon the interaction of 3a with m-chloroperbenzoic acid, the S-dioxide (4a) was obtained. Compound 5a was prepared from 4a by alkaline hydrolysis. Vilsmeier formylation for 1a--e produced novel [2-[p-(un)substituted phenyl]imidazo[2,1-b]benzothiazol-3- yl]formaldehyde derivatives (6a--e). Derivatives 6a--e reacted with ethyl bromoacetate to give ethyl 3-hydroxy-3-[2-[p-(un)substituted phenyl]imidazo[2,1-b]benzothiazol- 3-yl]propionate esters (7a--e). Compound dl-7a was resolved with l-(+)-tartaric acid. Compounds 2a--e showed weak or no activity in the carrageein-induced paw edema assay. Compound 4a significantly inhibited the leakage of pontamine-sky blue dye into the peritoneal cavity of mice, in the capillary permeability inhibition assay. Compound 5a inhibited the writhing by 62% in the acetic acid-induced writhing assay.     

Synthesis of 5-[2-(Phenoxy)ethyl] Derivatives of 6-Methyluracil, 6-Methyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one,and 2-Imino-6-methyl-2,3-dihydro-1H-pyrimidin-4-one

A synthesis of novel derivatives of 6-methyluracil, 6-methyl-2-thioxo-, and 2-imino-6-methyl-2,3-dihydro-1H-pyrimidin-4-one containing a 2-(phenoxy)ethyl substituent at position 5 of the pyrimidine ring has been carried out. It was found that 5-[2-(phenoxy)ethyl] derivatives of 6-methyl-2-thioxo- and 2-imino-6-methyl-2,3-dihydro-1H-pyrimidin-4-one are obtained by the condensation of the corresponding ethyl 3-oxo-2-(2-phenoxyethyl)butanoates with thiourea or guanidine. 6-Methyl-5-[2-(phenoxy)ethyl]uracils can be prepared by treating 6-methyl-5-[2-(phenoxy)ethyl]-2-thioxo-2,3-dihydro-1H-pyrimidin-4-ones with an excess of aqueous monochloroacetic acid solution. __________ Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 8, pp. 1213–1217, August, 2005.     

Synthesis of some new pyrimidine selanyl derivatives

The targeted synthesis of 2-(methylsulfanyl)-6-(furan-2-yl)-4(3H)-selenoxo -pyrimidine-5-carbonitrile failed due to the formation 1-methyl-2-methylsulfanyl-6-oxo -4-(furan-2-yl)-1,6-dihydropyrimidine-5-carbonitrile. A new series of 5,6,7,8-tetrahydro-1-benzo thieno[2,3-d]pyrimidine-4-yl substituted selanyl derivatives were prepared by the reaction of sodium diselenide with 4-chloro-5,6,7,8-tetrahydro-1-benzothieno[2,3-d]pyrimidine followed by the reaction with chloroacetic acid derivatives such as ethyl chloroacetate, chloroacetamide or chloroacetonitrile. Hydrazinolysis of ethyl (5,6,7,8-tetrahydro-1-benzothieno[2,3-d]pyrimidine- 4-ylselanyl)acetate with hydrazine hydrate gave the corresponding hydrazino derivative. The latter reacted with ethyl acetoacetate, acetylacetone, diethyl malonate, ethoxymethylenemalononitrile or ethyl 2-cyano-3-ethoxyacetate to afford 5-methyl-2-[2-(5,6,7,8-tetrahydro-1-benzothieno [2,3-d]pyrimidine-4-ylselanyl)acetyl]-2,4-dihydropyrazol-3-one, 1-(3,5-dimethylpyrazol-1-yl)-2- (5,6,7,8-tetrahydro-1-benzothieno[2,3-d]pyrimidin-4-ylselanyl)ethanone, 1-[2-(5,6,7,8-tetrahydro -1-benzothieno[2,3-d]pyrimidine-4-ylselanyl)acetyl]-2,4-dihydropyrazolidine-3,5-dione and 5-Amino-1-[2-(5,6,7,8-tetrahydro-1-benzothieno[2,3-d]pyrimidin-4-ylselanyl)acetyl]-1H-pyrazol -4-yl substituted carbonitrile or ethyl carboxylate, respectively. The structure of the novel compounds was confirmed by spectroscopic tools (IR, ¹H NMR ¹³C NMR and mass spectra) and elemental analysis.     

Synthesis of 3-arylsulfonylmethyl-1,2,4-oxadiazole-5-carboxylic acid derivatives

Several new 3-arylsulfonylmethyl-1,2,4-oxadiazole-5-carboxylic acid derivatives have been synthesized. A typical example, 3-[(4-chlorophenylsulfonyl)methyl]-1,2,4-oxadiazole-5-carboxylic acid ethyl ester ( 2c ), was prepared from the reaction of 2-(4-chlorophenylsulfonyl)acetamide oxime ( 1c ) with ethyl oxalyl chloride. The hydrazide derivative ( 3f ) showed antihypertensive activity in rats. Various structural modifications to improve activity are discussed.     

A concise synthesis of a very late antigen-4 antagonist trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxyamide)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid via reductive etherification

This contribution describes a concise synthesis to ethyl trans-[(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate (2b) as a key intermediate of very late antigen-4 (VLA-4) antagonist trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxyamide)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid (1). The synthesis employs a reductive etherification as a key reaction using (2S,4S)-1-benzyloxycarbonyl-4-methoxypyrrolidine-2-carboxyaldehyde (12) and trans-4-triethylsilyloxycyclohexanecarboxilic acid ethyl ester (13b). This synthesis provides 2b in 6 steps with 38% overall yield from commercially available starting material.